ArticleFrontiers in immunology2025

Potentiating T cell tumor targeting using a combination of TCR with a Siglec-7 based CSR.

Shiran Didi-Zurinam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.